Quality, Affordable and Accessible

Sinophi Signs Agreement for Proton Centre with China-Japan Union Hospital of Jilin University

On July 27th 2015 in Changchun, Jilin province, China, Sinophi Healthcare signed an agreement with China-Japan Union Hospital of Jilin University (CJUHJU) for a Proton Center at CJUHJU in Changchun. The Proton Center will include a proton therapy machine from Advanced Oncotherapy plc of the UK, using world-leading advanced proton technology developed at CERN in Switzerland. Changchun Vice Mayor Madame Zhang Jing Ying, Jilin University President Mr Li Yuan Yuan and China Development Bank Jilin Province Deputy General Manager Mr Zhang Zhao Yi attended the signing ceremony together with Mr Brian Gallagher, Director, UKTI China representing the UK Government. The agreement was signed by Professor Zhao Guo Qing, President of CJUHJU and Dr Hanif Kanji, CEO of Sinophi Healthcare.

Commenting on the agreement, Mr Li Yuan Yuan, President of Jilin University, said: “I believe Sinophi Healthcare and the China-Japan Union Hospital of Jilin University will be a powerful combination, with the construction of a proton therapy center a mutually beneficial opportunity which will also create other opportunities and platforms. Jilin University is delighted to support this advanced scientific and technological project to bring to Changchun, Jilin and China the latest proton treatment to relieve the pain of cancer patients.

Commenting on the agreement, Professor Zhao Guo Qing, President of China-Japan Union Hospital of Jilin University, said: “Our hospital’s cooperation with Sinophi Healthcare to build a proton therapy center will enable us to lead in developing the next generation of proton therapy in China. It will give our physicians new tools to treat cancer patients and to contribute to improving the healthcare of the citizens we serve in Changchun City, in Jilin Province and throughout northeast China.”

Commenting on the agreement, Dr Hanif Kanji, CEO of Sinophi Healthcare said: “The Sinophi Proton Center in Changchun continues Sinophi’s commitment to work with leading Chinese hospitals to support the objectives of China’s healthcare reform programme. Our cooperation with China-Japan Union Hospital of Jilin University is our first investment in next generation, high precision medicine in China. Our goal is to reduce the equipment, operation and maintenance costs of proton radiotherapy so many more cancer patients can have access to the benefits of proton therapy in China. This Sinophi Proton Center is a wonderful example of making the benefits of a major breakthrough in medical technology available to all people.

About China-Japan Union Hospital of Jilin University

CJUHJI is located in Changchun in Jilin province and is one of north-east China’s leading hospitals. Founded in 1949 and formerly known as the Number 3 Affiliated Hospital of the Norman Bethune Medical University, today it is a AAA grade hospital with 3,328 in-patient beds. Under the direct jurisdiction of the National Health and Family Planning Commission and affiliated to Jilin University under the Education Ministry of China, CJUHJI integrates medical care, education, research, disease-prevention, healthcare and rehabilitation into one institution.

About Jilin University
Located in Changchun City, Jilin University is one of China’s leading universities and one of the largest, with over 60,000 students. Jilin University has established ties with 130 universities, colleges and research institutes in 40 countries. In addition to the China-Japan Union Hospital, the Changchun No 1 and No 2 Hospitals are also part of Jilin University.

About Changchun City
Changchun City has a population of more than 7.8 million and is the provincial capital of Jilin province (population 27 million). Known as China’s leading manufacturing location for automobiles and transportation equipment and as a major film production center, Changchun is a leading city in the north-east China region.

About proton therapy
There are three main forms of treatment for cancer: surgery, chemotherapy and radiotherapy. X-ray radiotherapy is the most used form of radiotherapy today. Proton therapy, using the energy released by protons to destroy cancer cells, is another form of radiotherapy. It is a validated treatment for cancer used since 1954, with more than 120,000 patients treated globally since then. Proton therapy is better able than X rays to target tumours and not surrounding organs, leading to reduced side effects and better quality of life for patients. It can reduce length of treatment and thus cost, and is particularly beneficial when tumours are located close to vital organs and for children with cancer.

About Advanced Oncotherapy plc  (www.avoplc.com)

Advanced Oncotherapy is a UK company listed on AIM on the London Stock Exchange (stock symbol: AVO).  Advanced Oncotherapy’s  subsidiary “ADAM”, a spin-off company from CERN based in Geneva, has developed the next-generation proton therapy systems for cancer treatment.  Advanced Oncotherapy and its LIGHT machine system greatly reduces the cost of proton beam therapy for cancer treatment and brings it within reach of many more patients.

About CERN  (www.cern.ch)
CERN is the European Centre for Nuclear Reasearch, located near Geneva in Switzerland.  CERN is one of the world’s largest and most respected centers for scientific research and the inventor of the most powerful particle accelerator ever built, the 27km Hadron Collider.

About Sinophi Healthcare  (www.sinophi.com)
Sinophi Healthcare is a UK company investing in and managing hospitals in China, focused on public general hospitals and selected specialty and super specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, building links with hospitals in the UK’s National Health Service system and partnerships with leading UK and international healthcare service and product partners.